Here are four things to know.
1. Novo Nordisk’s Xultophy and Sanofi’s Soliqua both combine long-acting insulin with a second type of medicine responsible for stimulating insulin production in the pancreas, according to the report.
2. Plainsboro, N.J.-based Novo Nordisk plans to launch Xultophy in the first half of 2017, taking extra me to negotiate reimbursement terms with insurers. Paris, France-based Sanofi plans to release Soliqua in January 2017.
3. Both drugmakers said the competing treatments will be sold at a lower price than the combined cost of the drugs’ ingredients, according to the report.
4. Industry analysts expect Xultophy to produce annual sales of about $1.20 billion in 2021 and predict Soliqua will only reach $550 million that same year, according to consensus estimates compiled by Thomson Reuters.
More articles on supply chain:
Gartner names top 25 supply chains in healthcare
More than two-thirds of hospital leaders expect to boost annual supply chain investment over next 3 years, survey finds
DHL Express will invest $185M in US operations to support increased shipping volumes: 3 takeaways
